IVBXF (Innovent Biologics) Other Current Liabilities : $318 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Innovent Biologics Other Current Liabilities?

Innovent Biologics's other current liabilities for the quarter that ended in Dec. 2024 was $318 Mil.

Innovent Biologics's quarterly other current liabilities declined from Dec. 2023 ($283 Mil) to Jun. 2024 ($277 Mil) but then increased from Jun. 2024 ($277 Mil) to Dec. 2024 ($318 Mil).

Innovent Biologics's annual other current liabilities increased from Dec. 2022 ($236 Mil) to Dec. 2023 ($283 Mil) and increased from Dec. 2023 ($283 Mil) to Dec. 2024 ($318 Mil).

Innovent Biologics Other Current Liabilities Historical Data

The historical data trend for Innovent Biologics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Other Current Liabilities Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Current Liabilities

Get a 7-Day Free Trial

117.76

268.61

235.64

283.01

317.97

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Current Liabilities	Get a 7-Day Free Trial												235.64	205.46	283.01	276.70	317.97

Innovent Biologics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Innovent Biologics Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (OTCPK:IVBXF) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

IVBIY:USA 01801:Hong Kong 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.